<DOC>
	<DOCNO>NCT00936780</DOCNO>
	<brief_summary>The primary objective Infinnium-Core™ Registry ass safety efficacy Infinnium-Core™ Paclitaxel Eluting Coronary Stent System de novo Coronary Lesions .</brief_summary>
	<brief_title>Infinnium-Core™ Registry Treatment Patients With De Novo Coronary Lesions</brief_title>
	<detailed_description>Infinnium-Core™ Registry multi-centric , prospective study . Approximately 150 patient enrol study . Patients follow two year post-procedure . Data analysis include statistically pre assign 20 % patient patient repeat angiography due complication . The diabetic patient specify high risk subset study .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . Eligible percutaneous coronary intervention ( PCI ) . 3 . Acceptable candidate CABG . 4 . Clinical evidence ischemic heart disease and/or positive territorial functional study . Documented stable angina pectoris ( ( Canadian Cardiovascular Society ( CCS ) Classification 1,2,3 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC IIIBC ) , document silent ischemia . 5 . The target lesion single de novo coronary artery lesion ≥ 50 % &lt; 100 % stenosis one major epicardial territory ( LAD , LCX RCA ) . A second target lesion another major epicardial vessel could treat second lesion fit inclusion/exclusion criterion receive type stent . 6 . The target lesion must cover one study stent , preferably margin 3 mm side lesion . 7 . The target lesion must ≤ 37 mm length visual estimate . 8 . The target reference vessel diameter must ≥ 2.5 mm ≤ 3.5 mm . 9 . Patient patient 's legal representative inform nature study agree provision provide write informed consent notify / approve Institutional Review Board/Ethics Committee clinical site . 1 . Female childbearing potential . 2 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 25 % . 3 . Evidence acute Qwave nonQwave myocardial infarction within 72 hour precede index procedure . 4 . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix® , Ceruvin ) ticlopidine ( Ticlid® ) , heparin , paclitaxel , cobalt , chromium , contrast agent ( adequately premedicated ) . 5 . A platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3,000 cells/mm3 . 6 . Acute chronic renal dysfunction ( creatinine &gt; 2.0 mg/dl &gt; 150 µmol/L ) . 7 . Target vessel evidence thrombus . 8 . Target vessel excessively tortuous make unsuitable proper stent delivery deployment . 9 . Previous bare metal stenting ( less 1 year ) anywhere within target vessel . 10 . Previous drugeluting stenting anywhere within epicardial vessel 11 . The target lesion require treatment device PTCA prior stent placement ( e.g. , limited , directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) 12 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede runoff . 13 . Heavily calcified lesion and/or calcify lesion successfully predilated . 14 . Target lesion locate supply arterial venous bypass graft . 15 . Ostial target lesion . 16 . Patient currently participate investigational drug device study , include followup period . 17 . Within 30 day prior procedure , patient undergone previous coronary interventional procedure kind . 18 . Within 60 day postprocedure , patient require planned interventional treatment nontarget vessel . Planned intervention target vessel index procedure allow . 19 . CVA within previous 6 month . 20 . Unprotected Left Main ( LM ) coronary artery disease ( stenosis &gt; 50 % ) . 21 . In investigator 's opinion , patient comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study . 22 . Planned surgery within 6 month index procedure . 23 . Life expectancy less 1 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Coronary stent</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Drug Eluting Stents ( DES )</keyword>
</DOC>